Peripheral blood mRNA-based prognostic model for progression to metastatic castration-resistant prostate cancer and identification of SLC6A8 as a glycolysis-promoting biomarker
Approximately 35% of patients with metastatic hormone-sensitive prostate cancer (mHSPC) progress to metastatic castration-resistant prostate cancer (mCRPC), highlighting the limitations of PSA as a stand-alone monitoring biomarker. This study aimed to construct a peripheral blood mRNA-based prognostic model for pro...